A Study of Olverembatinib in the Treatment of Myeloid/Lymphoid Tumors With FGFR1 Rearrangement

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Feb 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Olverembatinib (Primary)
Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Myeloproliferative disorders; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use

06 Nov 2024 According to an Ascentage Pharma media release, data from this trial to be presented, at the 66th American Society of Hematology (ASH) Annual Meeting. The 66th ASH Annual Meeting will take place on Dec 7-10, 2024, local time, both online and in-person in San Diego, CA (United States).
06 Nov 2024 According to an Ascentage Pharma media release, the results form this trial will be presented at the 66th ASH Annual Meeting that swill take place on December 7-10, 2024.
02 Sep 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com